Recent Updates
Recently added Catalysts
NTRA Positive Sentiment Score: 85/100

Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

Wednesday, July 22, 2026 1 min read
Key Takeaway: Natera, Inc. announced that its Signatera test significantly outperformed the AMERK test in predicting recurrence of Merkel cell carcinoma (MCC), as published in JAMA Dermatology. The study demonstrated that Signatera not only provided stronger predictive capabilities but also detected relapses earlier than AMERK. This advancement highlights the potential of Signatera in improving patient outcomes in MCC.

Market Sentiment Analysis

POSITIVE FACTORS

  • Signatera test shows superior predictive ability for MCC recurrence.
  • Earlier detection of relapse compared to AMERK test.
  • Results published in a reputable journal (JAMA Dermatology).

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected relapse earlier.MCC is a rare but aggressive ski

Frequently Asked Questions

What is the Signatera test?

The Signatera test is a precision medicine tool used to predict cancer recurrence.

How does Signatera compare to AMERK?

Signatera significantly outperformed AMERK in predicting recurrence of Merkel cell carcinoma.

Where were the study results published?

The results were published in JAMA Dermatology.

What type of cancer is the study focused on?

The study focuses on Merkel cell carcinoma, a rare and aggressive skin cancer.

Tags: NTRA Viatris Investor Conferences Healthcare Natera Merkel cell carcinoma Signatera AMERK JAMA Dermatology
Last updated: Jul 22, 2026